Abstract The Oxford International Symposium on myocardial preservation provided an
appropriate milestone and impetus to survey one aspect of operative myocardial …

Calcium antagonists have become accepted agents for the attenuation of myocardial
ischemia when it becomes manifest as angina pectoris. However, it is not known whether …

To determine if, during elective cardiac arrest, the myocardial protection afforded by a cold
(4° C) crystalloid potassium cardioplegic solution could be improved by oxygenation of the …

An ATP-sparing effect has been demonstrated for a number of calcium antagonists.
Nifedipine probably has a similar action, but data supporting this view are limited. Therefore …

A clinical trial of nifedipine, a calcium antagonist, in cardioplegic solution was performed
based on previous laboratory data demonstrating improved postischemic performance in …

Despite the use of cold blood potassium (CBK) cardioplegia, the severely impaired
myocardium and/or long ischemia time continue to be a challenge. Because of the …

The calcium channel blocker, diltiazem, has been studied in the same model used for
evaluation of cold blood–potassium cardioplegia. Six dogs (Group 1) had one hour of …

Previous animal studies and a preliminary clinical trial of the addition of nifedipine to
cardioplegic solution demonstrated salutary effects in terms of postischemic performance …

This study analyzes the effects of intraoperative and postoperative calcium channel blockers
on myocardial protection, postoperative arrhythmias, perioperative infarctions, and survival …

This report summarizes five years of laboratory investigations and the initial six-month
clinical experience with a calcium antagonist, nifedipine, added to a cold hyperkalcmic …